Vlaamse Federatie van Beleggers

05/11/2024 UCB - Media Room: UCB completes sale of established brands and updates 2024 financial guidance (05.11.2024)

31/10/2024 UCB - Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024 (31.10.2024)

22/10/2024 UCB - Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting (22.10.2024)

14/10/2024 UCB - receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX (bimekizumab-bkzx) (14.10.2024)

11/10/2024 UCB - showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting (11.10.2024)

04/10/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (04.10.2024)

02/10/2024 UCB - Transparantieverklaring BlackRock, Inc. (02.10.2024)

01/10/2024 UCB - Transparantieverklaring BlackRock, Inc. (0110.24)

30/09/2024 UCB - announces a head-to-head study evaluating BIMZEL(bimekizumab) versus SKYRIZI (risankizumab) in active psoriatic arthritis (30.09.2024)

27/09/2024 UCB - Media Room: late-breaking two-year data for BIMZEL(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 (27.09.2024)

27/09/2024 UCB - Transparantieverklaring BlackRock, Inc. (27.09.2024)

26/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (26.09.2024)

25/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (25.09.2024)

25/09/2024 UCB - Media Room: New 4-year data for BIMZELX (bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 (25.09.2024)

24/09/2024 UCB - Media Room: Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in SLE (24.09.2024)

23/09/2024 UCB - announces U.S. FDA approvals for BIMZELX (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis (23.09.2024)

09/09/2024 UCB - New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease (09.09.2024)

07/09/2024 UCB - Transparantieverklaring BlackRock, Inc.(07.09.2024)

06/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc.(06.09.2024)

06/09/2024 UCB - Media Room: new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC) (06.09.2024)

05/09/2024 UCB - Transparantieverklaring BlackRock, Inc.(05.09.2024)

03/09/2024 UCB - Transparantieverklaring BlackRock, Inc. (03.09.2024)

29/08/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (29.08.2024)

26/08/2024 UCB - Media Room: UCB to Accelerate Innovation and Strategic Partnerships, Divesting Mature Product Portfolio in China

24/08/2024 UCB - Transparantieverklaring BlackRock, Inc. (24.08.2024)

22/08/2024 UCB- Transparantieverklaring BlackRock, Inc. (22.08.2024)

10/08/2024 UCB - Media Room: Transparency notification (10.08.2024)

09/08/2024 UCB - Transparantieverklaring Goldman Sachs (09.08.2024)

08/08/2024 UCB - Transparency notification Goldman Sachs (08.08.2024)

05/08/2024 UCB announces European Commission approval for 320 mg device presentations of BIMZELX(bimekizumab) - 05.08.2024

25/07/2024 UCB - Sterke start van UCB’s decennium van groei (25.07.2024)

28/06/2024 UCB - spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN) (28.06.2024)

26/06/2024 UCB - epilepsy drug BRIVIACT(brivaracetam)1 approved in Japan for treatment of focal onset seizures (26.06.2024)

13/06/2024 UCB -New data support the value of CIMZIA for women living with chronic rheumatic diseases throughout pregnancy and postpartum, and for people living with RA and high rheumatoid factor levels (13.06.2024)

12/06/2024 UCB - to share first presentations of BIMZELX(bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 (12.06.2024)

10/06/2024 UCB - Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps (10.06.2024)

31/05/2024 UCB - announces positive CHMP opinion for two 320 mg device presentations of BIMZELX (bimekizumab) (31.05.2024)

23/05/2024 UCB - announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa (23.05.2024)

18/05/2024 UCB - Media Room: Transparency notification Wellington (18.05.2024)

08/05/2024 UCB - Media Room: UCB presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting (08.05.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - Media Room UCB’s General Meeting of Shareholders 2024 (25.04.2024

24/04/2024 UCB - Transparantieverklaring FMR LLC (24.04.2024)

22/04/2024 UCB - receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa (22.04.2024)

17/04/2024 UCB - FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (17.04.2014)

12/04/2024 UCB - Media Room: UCB presents new data highlighting developments across expansive neurology portfolio at 76th AAN Annual Meeting (12.04.2024)

12/04/2024 UCB - Media Room: Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY(romosozumab) can help to close the treatment gap in osteoporosi (12.04.2024)

04/04/2024 UCB - FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations (04.04.2024)

22/03/2024 UCB - receives positive CHMP opinion for BIMZELX®▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (22.03.2024)

08/03/2024 UCB - Bimekizumab 48-week Phase 3 analyses in moderate to severe hidradenitis suppurativa showed sustained improvements in skin pain and draining tunnel count (08.03.2024)

04/03/2024 UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases (04.03.2024)

28/02/2024 UCB - FY Results 2023 (28.02.2024)

09/02/2024 UCB - Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024 (09.02.2024)

08/01/2024 UCB- announces European Commission approval of RYSTIGGO (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe (08.01.2024)

27/12/2023 UCB - BIMZELX (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis (27/12/2023)

04/12/2023 UCB - announces European Commission approval of ZILBRYSQ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis (04.12.2023)

01/12/2023 UCB - presents new data advancing patientfocused scientific leadership at American Epilepsy Society Annual Meeting (01.12.2023)

16/11/2023 UCB - ‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements (16.11.2023)

13/11/2023 UCB - Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels (13.11.2023)

10/11/2023 UCB - CHMP positive opinion for rozanolixizumab for treatment of adults with generalized myasthenia gravis in Europe (10.11.2023)

09/11/2023 UCB - rondt de aanbieding aan het publiek van vastrentende obligaties met succes af en beslist om de inschrijvingsperiode vroegtijdig te beëindigen (09.11.2023)

18/10/2023 UCB - announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis (18.10.2023)

18/10/2023 UCB - BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis (18.10.2023)

12/10/2023 UCB - Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa (12.10.2023)

09/10/2023 UCB - to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023 09.10.2023)

25/09/2023 UCB - announces approval of RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan (25.09.2023)

15/09/2023 UCB - receives CHMP positive opinion of zilucoplan for the treatment of adults with generalized myasthenia gravis in Europe (15.09.2023)

31/08/2023 UCB - presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla®▼(fenfluramine) oral solution and broader epilepsies portfolio (31.08.2023)

27/07/2023 UCB - Media Room : Half Year Results 2023 (27.07.2023)

18/07/2023 UCB - Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa (18.07.2023)

27/06/2023 UCB - Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab (26.06.2023)

27/06/2023 UCB - announces U.S. FDA approval of RYSTIGGO (27.06.2023)

26/06/2023 UCB - Change in UCB’s Executive Committee (26.06.2023)

20/06/2023 UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress (20.06.2023)

07/06/2023 UCB - Receives New European Commission Approvals for BIMZELX®▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis (07.06.2023)

31/05/2023 UCB - New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023 (31.05.2023)

30/05/2023 UCB - Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023 (30.05.2023)

23/05/2023 UCB - and Veeva collaborate to advance the patient experience in clinical trials (23.05.2023)

11/05/2023 UCB - and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer (11.05.2023)

27/04/2023 UCB - Receives Positive CHMP Opinions for Bimekizumab (27.04.23)

13/04/2023 UCB - Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal (13.04.2023)

19/03/2023 UCB - Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks (19.03.2023)

16/03/2023 UCB - to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis and Hidradenitis Suppurativa (16.03.2023)

15/03/2023 UCB - Aitia Collaboration in Huntington's Disease (15.03.2023)

09/03/2023 UCB - Cancer Research UK Signs Multi-Project Collaboration With UCB To Advance Oncology Antibody Candidates (09.03.2023)

22/02/2023 UCB - is goed omgegaan met de uitdagingen in 2022 en is klaar voor lanceringen in 2023 (22.02.2023)

08/02/2023 UCB - FINTEPLA (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (08.02.2023)

18/01/2023 UCB - Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis (18.01.2023)

09/01/2023 UCB - financial update (09.01.2023)

23/12/2022 UCB - Announces FDA Acceptance of BLA Resubmission for Bimekizumab (23.12.2022)

19/12/2022 UCB - FINTEPLA (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (19.12.2021)

14/12/2022 UCB - and Praxis Precision Medicines Announce Epilepsy Research Collaboration (14.12.2022)

09/12/2022 UCB - Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa (09.12.2022)

07/12/2022 UCB - The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis (07.12.2022)

23/11/2022 UCB - Submits Response to FDA Complete Response Letter for Bimekizumab (23.11.2022)

14/11/2022 UCB Media Room - U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients (14.11.2022)

10/11/2022 UCB - Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis (10.11.2022)

08/11/2022 UCB - Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022 (08.11.2022)

27/09/2022 UCB - FINTEPLA (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome (27.09.2022)

22/09/2022 UCB - presents latest data from generalized myasthenia gravis portfolio at AANEM meeting (22.09.2022)

20/09/2022 UCB - European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis (20.09.2022)

09/09/2022 UCB - ASBMR 2022: 3D modelling of hip DXA scans in postmenopausal women with osteoporosis reveals superior improvements in bone density of romosozumab versus controls (09.09.2022)

07/09/2022 UCB - New Three-Year BIMZELX (bimekizumab) Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis (07.09.2022)

28/07/2022 UCB - Strong first six months – UCB with continued delivery and strong resilience (28.07.2022)

24/06/2022 UCB - UCB updates financial guidance for 2022 while maintaining 2025 financial guidance (24.06.2022)

23/05/2022 UCB - Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 (23.05.2022)

23/05/2022 UCB - First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

13/05/2022 UCB - Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab (13.05.2022)

10/05/2022 UCB - presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis (10.05.2022)

02/05/2022 UCB - JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA (fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) (02.05.2022)

28/03/2022 UCB - New Long-Term Complete Skin Clearance Data for BIMZELX®▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting (28.03.2022)

28/03/2022 UCB - U.S. FDA Approves FINTEPLA® (fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) (28.03.2022)

08/03/2022 UCB - UCB expands innovation footprint with new state-of-the-art gene therapy facility (08.03.2022)

28/02/2022 UCB - Announces Extension of Tender Offer to Acquire Zogenix, Inc. (28.02.2022)

24/02/2022 UCB - Resultaten - Uitvoering van de strategie en verbintenissen van UCB (24.02.2022)

04/02/2022 UCB - announces positive data in myasthenia gravis with zilucoplan phase 3 study results (04.02.2022)

02/02/2022 UCB - UCB ontvangt positief CHMP-advies waarin goedkeuring wordt aanbevolen van BRIVIACT ® (brivaracetam) en VIMPAT ® (lacosamide) in de EU voor partieel beginnende aanvallen bij pediatrische patiënten van twee tot vier jaar (02.02.2022)

01/02/2022 UCB - Commences Tender Offer to Acquire Zogenix, Inc (01.02.2022)

24/01/2022 UCB - BIMZELX® (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma (24.01.2022)

21/01/2022 UCB - Positive Top-Line Results for BIMZELX®▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study (21.01.2022)

19/01/2022 UCB - neemt Zogenix over (19.01.2022)

18/01/2022 UCB - Positive Top-Line Results for BIMZELX®▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study (18.01.2022)

16/12/2021 UCB - Positive Top-Line Results for BIMZELX®▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial (16.12.2021)

10/12/2021 UCB - Positieve Fase 3-resultaten voor rozanolixizumab bij gegeneraliseerde myasthenia gravis (10.12.2021)

03/12/2021 UCB - to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care (03.12.2021)

02/12/2021 UCB - Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease (02.12.2021)

30/11/2021 UCB - en Chiesi sluiten wereldwijde licentieovereenkomst voor zampilimab, een nieuw monoklonaal antilichaam voor fibrotische longziekten (30.11.2021)

19/11/2021 UCB - Positive Top-Line Results from BIMZELX®▼(bimekizumab) Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms (19.11.2021)

27/10/2021 UCB - Unique patient-led and co-authored analysis of the experience of living with myasthenia gravis published in Neurology and Therapy (27.10.2021)

20/10/2021 UCB - to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab (20.10.2021)

18/10/2021 UCB - Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab (18.10.2021)

29/09/2021 UCB - New BIMZELX (bimekizumab) two-year data in moderate to severe plaque psoriasis presented at the 30th European Academy of Dermatology and Venereology (EADV) Congress (29.09.2021)

06/09/2021 UCB - BIMZELX (bimekizumab) ontvangt de eerste positieve beoordeling van gezondheidstechnologie wereldwijd (06.09.2021)

24/08/2021 UCB - Announces European Commission Approval of BIMZELX®▼(bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis (24.08.2021)

16/08/2021 5 favoriete aandelen van Patrick Nollet

29/07/2021 UCB - Eerste halfjaar 2021 met duurzame prestaties – realisatie van UCB's strategie en vooruitzichten (29.07.2021)

26/06/2021 UCB - Receives Positive CHMP Opinion Recommending Approval of BIMZELX®* (bimekizumab) in the EU for the Treatment of Adults with Moderate to Severe Plaque Psoriasis (25.06.2021)

01/06/2021 UCB - EULAR 2021: New Data from UCB’s Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age (01.06.2021)

28/04/2021 UCB - UCB Announces PDUFA Date for Bimekizumab (28.04.2021)

23/04/2021 UCB’ - zilucoplan shows no relevant effect in immunemediated necrotizing myopathy (IMNM)

14/04/2021 UCB - Kennisgeving van vervroegde terugbetaling – €350 miljoen € 1,875% vastrentende obligaties met vervaldatum 2 april 2022 (14.04.2021)

24/03/2021 UCB voltooit een aanbod van Euro-obligaties voor institutionele beleggers (24.03.2021)

19/03/2021 UCB krijgt CE-markering voor ava Connect®, een eersteklas elektromechanisch apparaat voor gebruik met biologische behandeling in reumatologie en dermatologie (19.03.2021)

25/02/2021 UCB - jaarresultaten (25.02.2021)

23/02/2021 UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development (23.02.2021)

28/01/2021 UCB - Community Health Fund zet zijn schouders onder 50 coronagerelateerde onderzoeksprojecten (28.01.2021)

13/01/2021 UCB - Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy (13.1.2020)

12/11/2020 UCB - strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms (12.11.2020)

22/10/2020 UCB - anti-epileptic drug VIMPAT (lacosamide) receives EU CHMP positive opinion (22.10.2020)

16/10/2020 UCB - FURTHER INVESTS IN UK OPERATIONS WITH AGREEMENT TO ACQUIRE A NEW LEADING-EDGE CAMPUS (16.10.2020)

22/09/2020 UCB - Achieves Important Regulatory Milestone for Bimekizumab (22.9.2020)

31/08/2020 UCB - Phase 3 data on VIMPAT published in Journal of Neurology, Neurosurgery & Psychiatry (31.8.2020)

29/07/2020 UCB -enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease (29.7.2020)

27/07/2020 UCB Half Year Report 2020

24/07/2020 UCB - Bimekizumab Superior to Cosentyx (24.7.2020)

07/07/2020 UCB - UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA for the Treatment of Adults with Moderate to Severe Crohn’s Disease (7.7.2020)

17/06/2020 UCB tackelt concurrentie in psoriasis (KBC)

09/01/2019 UCB: Japan opent deur voor Evenity (KBC)

18/10/2018 UCB (Jefferies)

13/09/2018 UCB (Jefferies)

26/04/2018 UCB (Jefferies)

23/02/2018 UCB (Jefferies)

20/10/2017 UCB: Stille waters hebben diepe gronden (BNPP Fortis)

22/05/2017 UCB: Oranje licht voor romo jaagt beleggers in de remmen (KBC, The Front Row)

06/07/2016 Morningstar: UCB

Artikels

Laatste nieuws

Aandeel in de kijker

Magazine

Analistenrapporten

Persberichten

Bedrijfsinfo

VFB Partners

Bedrijfsbezoeken

Financiële kalender

Opleiding

Evenementen

FAQ

Clubs

Trefpunten

Nieuws over Ucb

Onze sponsors

Snel naar

Nog niet gevonden wat u zocht?

Email

Helpdesk

Adres

Algemeen

Nieuws

Bedrijfsinfo

Opleiding

Evenementen

Clubs & Trefpunten

VFB is a member of Better Finance